Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies
UPDATED 05/07/2012. Increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma in patients being treated with Revlimid.